In one paragraphArticle in medRxiv : the preprint server for health sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
29 authors.
Gabriel C ScachettiLaboratory of Emerging Viruses, Department of Genetics, Evolution, Microbiology and Immunology, Institute of Biology, University of Campinas, Campinas, Brazil.ORCID 0000-0002-6633-5239 Julia ForatoLaboratory of Emerging Viruses, Department of Genetics, Evolution, Microbiology and Immunology, Institute of Biology, University of Campinas, Campinas, Brazil.ORCID 0000-0002-6247-9657 Ingra M ClaroDepartment of Microbiology, Immunology, and Molecular Genetics, College of Medicine, University of Kentucky, Lexington, KY, USA.ORCID 0000-0001-8637-2910 Xinyi HuaDepartment of Microbiology, Immunology, and Molecular Genetics, College of Medicine, University of Kentucky, Lexington, KY, USA.ORCID 0000-0001-9368-1228 Bárbara B SalgadoLaboratory of Infectious Diseases and Immunology, Instituto Leônidas e Maria Deane, Fiocruz Amazônia, Manaus, Brazil.ORCID 0000-0002-5318-1680 Aline VieiraLaboratory of Emerging Viruses, Department of Genetics, Evolution, Microbiology and Immunology, Institute of Biology, University of Campinas, Campinas, Brazil.
Camila L SimeoniLaboratory of Emerging Viruses, Department of Genetics, Evolution, Microbiology and Immunology, Institute of Biology, University of Campinas, Campinas, Brazil.ORCID 0000-0003-2288-5500 Aguyda R C BarbosaLaboratory of Infectious Diseases and Immunology, Instituto Leônidas e Maria Deane, Fiocruz Amazônia, Manaus, Brazil.ORCID 0000-0002-3644-9147 Italo L RosaLaboratory of Infectious Diseases and Immunology, Instituto Leônidas e Maria Deane, Fiocruz Amazônia, Manaus, Brazil.ORCID 0000-0002-8321-3241 Gabriela F de SouzaLaboratory of Emerging Viruses, Department of Genetics, Evolution, Microbiology and Immunology, Institute of Biology, University of Campinas, Campinas, Brazil.ORCID 0000-0001-7285-0790 Luana C N FernandesLaboratory of Infectious Diseases and Immunology, Instituto Leônidas e Maria Deane, Fiocruz Amazônia, Manaus, Brazil.ORCID 0000-0002-2798-8974 Ana Carla H de SenaLaboratory of Infectious Diseases and Immunology, Instituto Leônidas e Maria Deane, Fiocruz Amazônia, Manaus, Brazil.
Stephanne C OliveiraLaboratory of Infectious Diseases and Immunology, Instituto Leônidas e Maria Deane, Fiocruz Amazônia, Manaus, Brazil.
Carolina M L SinghLaboratory of Infectious Diseases and Immunology, Instituto Leônidas e Maria Deane, Fiocruz Amazônia, Manaus, Brazil.ORCID 0000-0002-6013-4647 Shirlene T de LimaLaboratory of Emerging Viruses, Department of Genetics, Evolution, Microbiology and Immunology, Institute of Biology, University of Campinas, Campinas, Brazil.ORCID 0000-0003-4738-9626 Ronaldo de JesusInstituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.ORCID 0000-0001-7340-2463 Mariana A CostaLaboratório Central de Saúde Pública do Acre, Rio Branco, Brazil.
Rodrigo B KatoInstituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.ORCID 0000-0002-9046-1702 Josilene F RochaLaboratório Central de Saúde Pública do Acre, Rio Branco, Brazil.
Leandro C SantosLaboratório Central de Saúde Pública do Acre, Rio Branco, Brazil.
Marielton P CunhaLaboratory of Emerging Viruses, Department of Genetics, Evolution, Microbiology and Immunology, Institute of Biology, University of Campinas, Campinas, Brazil.ORCID 0000-0002-2102-631X Ester C SabinoInstituto de Medicina Tropical, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.ORCID 0000-0003-2623-5126 Nuno R FariaDepartamento de de Patologia, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.ORCID 0000-0001-8839-2798 Scott C WeaverDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, USA.ORCID 0000-0001-8016-8556 Camila M RomanoDepartamento de de Patologia, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.ORCID 0000-0003-4550-1987 Pritesh LalwaniLaboratory of Infectious Diseases and Immunology, Instituto Leônidas e Maria Deane, Fiocruz Amazônia, Manaus, Brazil.ORCID 0000-0003-2996-0446 José Luiz Proença-MódenaLaboratory of Emerging Viruses, Department of Genetics, Evolution, Microbiology and Immunology, Institute of Biology, University of Campinas, Campinas, Brazil.ORCID 0000-0002-4996-3153 William M de SouzaDepartment of Microbiology, Immunology, and Molecular Genetics, College of Medicine, University of Kentucky, Lexington, KY, USA.ORCID 0000-0002-0025-8293 Funding
World Reference Center for Emerging Viruses and Arboviruses (WRCEVA)R24AI120942 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI WEAVER, SCOTT C · 2016 to 2024
$8.5MNIAID NIH HHS R24 AI120942Wellcome Trust
6 · The paper itselfAbstract
Background: Oropouche virus (OROV; species Methods: In this study, we combined OROV genomic, molecular, and serological data from Brazil from 1 January 2015 to 29 June 2024, along with Findings: In 2024, autochthonous OROV infections were detected in previously non-endemic areas across all five Brazilian regions. Cases were reported in 19 of 27 federal units, with 83.2% (6,895 of 8,284) of infections in Northern Brazil and a nearly 200-fold increase in incidence compared to reported cases over the last decade. We detected OROV RNA in 10.8% (10 of 93) of patients with febrile illness between December 2023 and May 2024 in Amazonas. We demonstrate that the 2023-2024 epidemic was caused by a novel OROV reassortant that replicated approximately 100-fold higher titers in mammalian cells compared to the prototype strain. The 2023-2024 OROV reassortant displayed plaques earlier than the prototype, produced 1.7 times more plaques, and plaque sizes were 2.5 larger compared to the prototype. Furthermore, serum collected in 2016 from previously OROV-infected individuals showed at least a 32-fold reduction in neutralizing capacity against the reassortment strain compared to the prototype. Interpretation: These findings provide a comprehensive assessment of Oropouche fever in Brazil and contribute to a better understanding of the 2023-2024 OROV reemergence. The recent increased incidence may be related to a higher replication efficiency of a new reassortant virus that also evades previous immunity.
Identifiers
PMID39132482
PMCPMC11312653
What Socratic holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390